(UroToday.com) Standard of care for high-risk non-muscle-invasive bladder cancer (NMIBC) is transurethral resection of the bladder tumor followed by intravesical Bacillus Calmette-Guérin (BCG) immunotherapy, although many patients will become BCG-unresponsive and experience recurrence within 12 months. Pembrolizumab was approved in January 2020 for treatment of patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected to not undergo cystectomy based on interim results from 96 patients in the open-label, single-arm, multicenter, Phase II KEYNOTE-057 (NCT02625961) study. At the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Arjun Balar and colleagues presented updated efficacy and safety results with an extended minimum follow-up of 26.3 months from KEYNOTE-057 cohort A.